Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

Long-Term Evaluation of BIIB067 (Tofersen)

Phase 3

Completed

Conditions: ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

Interventions: Drug: Tofersen

First Posted Date: 2017-03-03

Last Posted Date: 2024-08-19

Lead Sponsor: Biogen

Target Recruit Count: 139

Registration Number: NCT03070119

Locations: 🇬🇧
Research Site, Sheffield, South Yorkshire, United Kingdom

802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia

Phase 3

Withdrawn

Conditions: Trigeminal Neuralgia

Interventions: Drug: Placebo
Drug: BIIB074

First Posted Date: 2017-03-03

Last Posted Date: 2023-05-06

Lead Sponsor: Biogen

Registration Number: NCT03070132

Study of BIIB092 in Participants With Progressive Supranuclear Palsy

Phase 2

Terminated

Conditions: Supranuclear Palsy, Progressive

Interventions: Drug: Placebo
Drug: BIIB092

First Posted Date: 2017-03-01

Last Posted Date: 2020-12-21

Lead Sponsor: Biogen

Target Recruit Count: 490

Registration Number: NCT03068468

Locations: 🇬🇧
Research Site, London, United Kingdom
🇺🇸
Research Name, Chicago, Illinois, United States

Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease

Phase 1

Completed

Conditions: Alzheimer's Disease
Healthy Volunteer

Interventions: Drug: BIIB076
Drug: Placebo

First Posted Date: 2017-02-17

Last Posted Date: 2020-03-24

Lead Sponsor: Biogen

Target Recruit Count: 46

Registration Number: NCT03056729

Locations: 🇺🇸
St Louis Clinical Trial, Saint Louis, Missouri, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
MD Clinical, Hallandale Beach, Florida, United States

and more 5 locations

A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease

Phase 2

Completed

Conditions: Parkinson Disease

Interventions: Drug: SAGE-217
Drug: Antiparkinsonian Agent(s)
Drug: Levodopa

First Posted Date: 2016-12-22

Last Posted Date: 2023-11-29

Lead Sponsor: Biogen

Target Recruit Count: 29

Registration Number: NCT03000569

Locations: 🇺🇸
Sage Investigational Site, Orem, Utah, United States

A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder

Phase 2

Completed

Conditions: Major Depression

Interventions: Drug: SAGE-217
Drug: Placebo

First Posted Date: 2016-12-22

Last Posted Date: 2023-11-28

Lead Sponsor: Biogen

Target Recruit Count: 102

Registration Number: NCT03000530

Locations: 🇺🇸
Sage Investigational Site, Charlottesville, Virginia, United States

MS PATHS Normative Sub-Study

Completed

Conditions: Healthy Volunteer

First Posted Date: 2016-12-19

Last Posted Date: 2023-02-24

Lead Sponsor: Biogen

Target Recruit Count: 246

Registration Number: NCT02996084

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇪🇸
Multiple Sclerosis Centre of Catalonia (Cemcat) Vall d'Hebron Hospital, Barcelona, Spain

and more 3 locations